📣From lead to pre-candidate nomination in 18 months. Explore the STORM Therapeutics case study

Contact
  • Integrated Drug Discovery

    Integrated Drug Discovery

    Overview

    We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.

  • Target Identification & Validation

    Target Identification & Validation

    It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.

  • Hit Identification

    Hit Identification

    Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.

  • Hit-to-Lead

    Hit-to-Lead

    High-quality hits with early proof of concept are de-risked and profiled, ready to accelerate your program towards lead optimization.

  • Lead Optimization

    Lead Optimization

    Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.

Featured Resources

  • Modalities

    Modalities

    Overview

    Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.

  • Small Molecules

    Small Molecules

    Expert small molecule discovery from target ID to scale-up, delivering candidates designed for success and market impact.

  • Peptides

    Peptides

    Transforming complex peptide concepts into next-generation therapies through integrated design, advanced analytics, and collaborative end-to-end discovery expertise.

  • Targeted protein degradation

    Targeted protein degradation

    Leveraging induced proximity and CHARMED technology to rapidly design, test, and optimize degraders for previously ‘undruggable’ targets.

  • ADCs

    ADCs

    Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.

  • Biologics

    Biologics

    Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.

Featured Resources

  • Therapeutic Areas

    Therapeutic Areas

    Overview

    Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

  • Oncology and Immuno-Oncology

    Oncology and Immuno-Oncology

    Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.

  • Inflammation and Immunology

    Inflammation and Immunology

    Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.

  • Neuroscience

    Neuroscience

    Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.

  • Metabolic Diseases

    Metabolic Diseases

    Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.

Featured Resources

  • CellCentric Lead Optimisation Campaign - CCS1477

    CellCentric Lead Optimisation Campaign - CCS1477

    Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.

    Case study
  • About Sygnature

    About Sygnature

    At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.

  • Meet our Team

    Meet our Team

    Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.

  • Careers

    Careers

    Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.

Search Results

Search across news, resources and pages to quickly find relevant content on our site.

Loading…
Webinars & Podcasts
Toxicity & Efficacy in ADCs: How to Get It Right
While others focus on a conventional and well trodden ADC development pathway, Allan Jordan (VP, Oncology Drug Discovery) and Josh Greally (ADC Lead) discuss new approaches. This includes a focus on payload optimisation to enhance a drug’s efficacy and selectivity, thereby maximizing its therapeutic benefit. Better performing end products lead to better patient outcomes.
Webinars & Podcasts
Next Generation ADCs: Can We Improve Drug Delivery Further
While others focus on a conventional and well trodden ADC development pathway, Allan Jordan (VP, Oncology Drug Discovery) and Josh Greally (ADC Lead) discuss new approaches. This includes a focus on payload optimisation to enhance a drug’s efficacy and selectivity, thereby maximizing its therapeutic benefit. Better performing end products lead to better patient outcomes.
Blog
Exploring new paths in ADC development
Antibody-drug conjugates (ADCs) represent an important approach to targeted cancer therapy, combining the…
Blog
What’s the Evolving Role of Medicinal Chemistry in ADC Development?
Antibody-drug conjugates (ADCs) are steadily gaining traction as a powerful approach in targeted…
Blog
Linker Technologies in ADCs: How They Impact Efficacy & Stability
Antibody-drug conjugates (ADCs) have revolutionized targeted cancer therapy, but discussions often focus on…
Blog
Toxicity & Efficacy in ADCs: How to Get it Right
Antibody-Drug Conjugates (ADCs) still face significant challenges related to patient tolerability and therapeutic…
Blog
3 Transformative Changes in ADC Development Over the Next Decade
Since Paul Ehrlich’s original ‘magic bullet’ concepts, antibody-drug conjugates (ADCs) have undergone significant…
Journal Papers
Discovery of RP-1664: A First-in-Class Orally Bioavailable, Selective PLK4 Inhibitor
Frédéric Vallée, Matias Casás-Selves, Monica Bubenik, Martin Duplessis, Boubacar Sow, Catalina Suarez, Bruno Sangiorgi, Li…
Blog
More Protein Targets More Cell Cultures
The dramatic rise in the number of cell expression grows, culture volumes and expressed protein…
Journal Papers
Validation, Key Pharmacophores, and X-ray Cocrystal Structures of Novel Biochemically and Cellularly Active WRN Inhibitors Derived from a DNA-Encoded Library Screen
Yunsong Tong, Kenton A. Baker, Alex M. Chapman, Nathaniel L. Elsen, Faith Fowler, Mariam D.
Blog
Advancing alternative modalities – ASMS screens rapidly find novel ligands agnostic to binding site
This case study demonstrates how ASMS screening using our compound collections…
Case Studies
RP-3500, Camonsertib®
WO 2025057106 A1 & J. Med. Chem. 2024, 67, 7, 10251-10284
News
Sygnature Discovery Completes Major Enhancement of High-Throughput Chemistry Facilities Following £1 Million Investment
Sygnature Discovery, a leading integrated drug discovery contract research organisation (CRO), today announces…
Blog
Why Membrane Proteins Matter – and Why They’re So Hard to Study!
Over the coming months, we’ll be sharing a series of blog posts and case studies…
Blog
Why Everyone’s Talking About Metabolic GPCRs
Importance of metabolic GPCRs Metabolic GPCRs play a vital role in how our bodies manage…
News
Dr Simon Hirst awarded prestigious honorary Doctorate from the University of Nottingham
Dr Simon Hirst, CEO and Founder of Sygnature Discovery has been awarded a prestigious honorary…
Blog
Meet the Membrane Protein Team
At Sygnature Discovery, our Protein Science department stands out for its expertise in expressing, purifying…
Case Studies
RP-6306, Lunresertib®
WO 2020/195781 A1 & J. Med. Chem. 2022, 65, 15, 10251-10284
Case Studies
Key Intermediate Rescue
WO 2020/078875 A1
Blog
Scaling with Confidence: Process Chemistry for Preclinical Success
Why Early Process Chemistry Matters Early-stage synthetic chemistry is designed for exploration. Medicinal chemists rightly…
Blog
From Analytical to Kilogram:How Advanced Separation Sciences Drive Discovery at Sygnature 
In modern drug discovery, speed and scale are everything. But achieving both, without compromising quality,…
Load More

Support

Can't find what you're looking for?

Can't find what you're looking for? Our team can help — whether you need assistance locating a resource, have a research enquiry, or want media information, get in touch and we'll point you in the right direction.

Get in touch